Perimenopausal Transition — MCQs
A middle-aged female presents with increasing visual loss, breast enlargement, and irregular menses. What is the most appropriate investigation to diagnose the underlying condition?
A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?
A 35-year-old woman presents with 4 months of amenorrhea, increased FSH, LH, and decreased estrogen. What is the most likely diagnosis?
The established benefits of estrogen replacement therapy in menopausal women include a reduction in all of the following EXCEPT
HRT in post-menopausal women is given for all except:
Calcified canal is explored with all of the given instruments except:
What is the most common symptom treated with hormone therapy (HT) in menopausal women?
A judge can ask clarifying questions when:
Day 20 of menstrual cycle falls under which phase?
Preferred treatment for menorrhagia in reproductive age group?
Perimenopausal Transition Indian Medical PG Practice Questions and MCQs
Question 1: A middle-aged female presents with increasing visual loss, breast enlargement, and irregular menses. What is the most appropriate investigation to diagnose the underlying condition?
- A. S. calcitonin
- B. S. prolactin (Correct Answer)
- C. S. hemoglobin concentration
- D. S. calcium
Explanation: ***S. prolactin*** - **Hyperprolactinemia** is the most likely cause of the presented symptoms: **galactorrhea** (**breast enlargement** with milk production), **amenorrhea** (**irregular menses**), and **visual field defects** due to a pituitary tumor compressing the optic chiasm [1]. - Measuring serum prolactin levels directly confirms or rules out **hyperprolactinemia**, guiding further management, including imaging of the pituitary gland if elevated [1]. *S. calcitonin* - **Calcitonin** is a hormone primarily involved in **calcium regulation** and is typically elevated in medullary thyroid carcinoma. - The presented symptoms (visual loss, breast enlargement, irregular menses) are not characteristic of elevated calcitonin levels or a **medullary thyroid carcinoma**. *S. hemoglobin concentration* - **Hemoglobin concentration** measures the amount of oxygen-carrying protein in red blood cells and is used to diagnose **anemia** or polycythemia. - While general labs might include this, it is not directly relevant to the specific constellation of symptoms pointing towards an **endocrine or pituitary issue**. *S. calcium* - **Serum calcium** levels are checked for disorders of calcium metabolism, such as **hyperparathyroidism** or hypocalcemia. - Though calcium is regulated by hormones, the symptoms of **visual loss**, **breast enlargement**, and **menstrual irregularities** are not typically associated with primary disturbances in calcium levels.
Question 2: A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?
- A. Estrogen plus progesterone (Correct Answer)
- B. Citalopram
- C. Estrogen
- D. Levothyroxine
Explanation: ***Estrogen plus progesterone*** - This patient's symptoms (hot flashes, night sweats, fatigue, sleep disturbance, irregular menses) are highly suggestive of **perimenopause/menopause**. **Hormone replacement therapy (HRT)** with estrogen and progesterone is the most effective treatment for managing severe menopausal symptoms. - Adding **progesterone** is crucial for women with an intact uterus to prevent **endometrial hyperplasia** and **endometrial cancer** caused by unopposed estrogen therapy. *Citalopram* - **Selective serotonin reuptake inhibitors (SSRIs)** like citalopram can reduce the frequency and severity of hot flashes, but they are generally reserved for women who cannot take or prefer not to take HRT due to contraindications or concerns. - SSRIs are less effective than HRT for severe vasomotor symptoms and do not address other menopausal symptoms like vaginal dryness or bone loss. *Estrogen* - While estrogen is the primary hormone for alleviating menopausal symptoms, administering **unopposed estrogen** to a woman with an intact uterus significantly increases the risk of **endometrial hyperplasia** and **endometrial carcinoma**. - Progesterone is necessary to counteract the proliferative effects of estrogen on the endometrium, preventing these risks. *Levothyroxine* - **Levothyroxine** is used to treat **hypothyroidism**, a condition that can cause fatigue, weight changes, and menstrual irregularities. - However, the patient's primary symptoms of prominent hot flashes and night sweats are not characteristic of hypothyroidism, and her physical examination is normal, making this diagnosis less likely.
Question 3: A 35-year-old woman presents with 4 months of amenorrhea, increased FSH, LH, and decreased estrogen. What is the most likely diagnosis?
- A. Premature ovarian insufficiency (Correct Answer)
- B. Menopause
- C. Late menopause
- D. Perimenopause
Explanation: ***Premature ovarian insufficiency (POI)*** - The patient's age (35 years) combined with 4 months of **amenorrhea**, increased **FSH** and **LH**, and decreased **estrogen** is characteristic of premature ovarian insufficiency (also called premature ovarian failure). - The hormonal profile (**hypergonadotropic hypogonadism**) indicates ovarian failure occurring before the age of **40 years**, which defines POI. - POI affects approximately **1% of women under 40** and can present with amenorrhea, infertility, and symptoms of estrogen deficiency. *Menopause* - Menopause is diagnosed after **12 consecutive months of amenorrhea** in a woman, typically occurring around age **51 years** (natural menopause). - While the hormonal profile of elevated FSH/LH and low estrogen is consistent with menopause, the patient's **age of 35 years** and **only 4 months of amenorrhea** do not meet the criteria for natural menopause. *Late menopause* - Late menopause refers to menopause occurring at a later age than average, typically after age **55 years**. - This diagnosis is completely inconsistent with the patient's age of 35 years. *Perimenopause* - Perimenopause is the transitional phase leading up to menopause, characterized by **irregular menstrual cycles** and **fluctuating hormone levels**. - While FSH levels may be elevated at times, perimenopause typically shows **variable hormone levels** rather than the sustained pattern of high FSH/LH with low estrogen seen in this case. - The **sustained amenorrhea** and pronounced hormonal shifts indicate ovarian failure (POI) rather than perimenopausal transition.
Question 4: The established benefits of estrogen replacement therapy in menopausal women include a reduction in all of the following EXCEPT
- A. Hot flushes
- B. Mood depression (Correct Answer)
- C. Atrophic vaginitis
- D. Osteoporosis
Explanation: ***Mood depression*** - While some women may experience mood changes during menopause, estrogen replacement therapy does not consistently or significantly reduce **mood depression**. - The relationship between estrogen and mood is complex, and depression in menopausal women often has **multifactorial causes** beyond hormonal changes. *Hot flushes* - Estrogen replacement therapy is highly effective in alleviating **vasomotor symptoms** such as hot flushes and night sweats [1, 2]. - These symptoms are directly linked to declining estrogen levels. *Atrophic vaginitis* - Estrogen therapy effectively treats **genitourinary syndrome of menopause** (GSM), including symptoms of atrophic vaginitis. - It restores the **vaginal epithelium**, increasing lubrication and reducing dryness, itching, and dyspareunia. *Osteoporosis* - Estrogen plays a crucial role in **bone density maintenance** and its decline at menopause contributes to accelerated bone loss. - Estrogen replacement therapy is a known treatment to prevent and manage **postmenopausal osteoporosis** by reducing bone turnover [1].
Question 5: HRT in post-menopausal women is given for all except:
- A. Hot flushes
- B. Prevention of coronary artery disease (Correct Answer)
- C. Vaginal dryness
- D. Prevention of osteoporosis
Explanation: ***Prevention of coronary artery disease*** - While previously thought to be protective, later studies like the **Women's Health Initiative (WHI)** demonstrated that HRT can actually **increase the risk of cardiovascular events**, especially when initiated years after menopause. - HRT is **not recommended for the primary or secondary prevention** of coronary artery disease. *Hot flushes* - **Hot flushes** (vasomotor symptoms) are a common and effective indication for HRT, significantly reducing their frequency and severity. - Estrogen therapy is considered the **most effective treatment** for moderate to severe hot flashes associated with menopause. *Vaginal dryness* - **Vaginal dryness** (vulvovaginal atrophy) is effectively treated by HRT, particularly with local estrogen therapy, by restoring vaginal tissue health. - Estrogen helps to **restore the thickness, elasticity, and lubrication** of the vaginal walls, alleviating discomfort. *Prevention of osteoporosis* - HRT, specifically estrogen, is effective in **preventing bone loss** and reducing the risk of **osteoporotic fractures** in postmenopausal women. - It maintains **bone mineral density** by inhibiting osteoclast activity and promoting osteoblast function.
Question 6: Calcified canal is explored with all of the given instruments except:
- A. 10 K file (Correct Answer)
- B. 6 K file
- C. C+ file
- D. Profinder
Explanation: ***10 K file*** - **#10 K-files** are typically used for initial negotiation of **larger, more accessible canals**, not for exploring highly calcified or severely constricted canals. - Their larger diameter (0.10 mm) makes them too stiff and prone to ledge formation or perforation in extremely calcified areas. *6 K file* - **#6 K-files** are extremely small and flexible (0.06 mm in diameter), making them ideal for initial penetration through tight, calcified canal orifices. - Their fine tip and flexibility help in navigating complex anatomy and overcoming initial resistance without causing iatrogenic damage. *C+ file* - **C+ files** are specifically designed for calcified or severely curved canals due to their **stiffer shaft, non-cutting tip**, and improved resistance to buckling. - They are offered in multiple diameters, including very small sizes like 06 and 08, which are suitable for initial exploration of challenging canal anatomy. *Profinder* - **ProFinder files** are specialized stainless steel hand files with a **triangular cross-section** and non-cutting tip, designed for initial negotiation of difficult and calcified canals. - Their enhanced tip design and shaft stiffness facilitate easy insertion into tight orifices and help maintain the canal pathway.
Question 7: What is the most common symptom treated with hormone therapy (HT) in menopausal women?
- A. Endometriosis
- B. Uterine bleeding
- C. Hot flashes (Correct Answer)
- D. Breast cancer
Explanation: ***Hot flashes*** - **Vasomotor symptoms**, including hot flashes and night sweats, are the most frequent and bothersome symptoms experienced by menopausal women, leading them to seek medical attention and hormone therapy. - HT is highly effective in reducing the frequency and severity of hot flashes by stabilizing **thermoregulation** in the hypothalamus. *Breast cancer* - **Breast cancer** is a potential risk associated with hormone therapy, particularly with combined estrogen-progestin therapy, not a symptom treated by HT. - Women with a history of breast cancer or those at high risk are generally advised against HT due to this increased risk. *Endometriosis* - While **estrogen-dependent diseases** like endometriosis can be aggravated by HRT, endometriosis itself is a condition that typically improves after menopause. - HT is not used to treat endometriosis; in certain cases, it might be used to manage menopausal symptoms in women with a history of endometriosis after specific surgical interventions. *Uterine bleeding* - **Uterine bleeding** can be a side effect of hormone therapy, especially when progestin is not adequately balanced with estrogen in women with a uterus. - Abnormal uterine bleeding is a symptom that requires investigation to rule out other causes, and it is not a primary symptom treated by HT.
Question 8: A judge can ask clarifying questions when:
- A. At any time during the proceedings (Correct Answer)
- B. Before cross-examination
- C. During witness testimony only
- D. After cross-examination
Explanation: ***At any time during the proceedings*** - A judge's primary role is to ensure **justice** and clarity in the courtroom. Therefore, they are permitted to ask **clarifying questions** at any juncture. - This ensures they understand the evidence, testimony, and arguments presented by all parties for a fair adjudication. *Before cross-examination* - While a judge can ask questions at this stage, limiting it to "before cross-examination" is **too restrictive** and does not accurately reflect their inherent authority throughout a trial. - Their ability to seek clarification is not bound by specific procedural intervals like the start of cross-examination. *During witness testimony only* - This option is **too narrow** as a judge may need to clarify points made during opening statements, closing arguments, or even legal motions, not just during direct or cross-examination of a witness. - Limiting it to witness testimony would **impede their ability** to fully understand all aspects of the case. *After cross exam* - This is also an **incomplete** statement, as waiting until after cross-examination could mean missing opportunities to clarify earlier ambiguities that might affect subsequent testimony or arguments. - A judge's power to clarify is **continuous** and not confined to the end of a specific examination phase.
Question 9: Day 20 of menstrual cycle falls under which phase?
- A. Menstrual phase
- B. Follicular phase
- C. Ovulation phase
- D. Luteal phase (Correct Answer)
Explanation: ***Luteal phase*** - The **luteal phase** typically starts after ovulation, around day 14, and lasts until menstruation begins, usually day 28 of a 28-day cycle. Therefore, **day 20 falls squarely within this phase**. - During this phase, the **corpus luteum** forms and produces **progesterone**, preparing the uterus for potential pregnancy. *Menstrual phase* - The **menstrual phase** is the period of shedding of the uterine lining, typically occurring from **day 1 to day 5** of the menstrual cycle. - Day 20 is well past this phase, during which bleeding and low hormone levels are characteristic. *Follicular phase* - The **follicular phase** starts on day 1 of menstruation and lasts until ovulation, usually around **day 13-14** in a 28-day cycle. - During this phase, follicles mature under the influence of **FSH** and **estrogen** levels rise. Day 20 is beyond this period. *Ovulation phase* - The **ovulation phase** is a short period, typically around **day 14** of a 28-day cycle, when the mature egg is released from the ovary. - This phase is brief and marks the transition from the follicular to the luteal phase, so day 20 is considerably after ovulation.
Question 10: Preferred treatment for menorrhagia in reproductive age group?
- A. Cu IUD
- B. Hysterectomy
- C. NOVA T
- D. OCPs (Correct Answer)
Explanation: ***OCPs*** - **Combined oral contraceptives (OCPs)** are a common and effective first-line treatment for menorrhagia in reproductive-aged women, particularly when contraception is also desired. - They work by stabilizing the **endometrial lining**, reducing menstrual blood loss and regulating cycles. *NOVA T* - NOVA T is a type of **copper IUD (intrauterine device)**, which is known to potentially *increase* menstrual bleeding and dysmenorrhea, making it unsuitable for menorrhagia. - Its primary function is contraception, not the management of heavy menstrual bleeding. *Cu IUD* - The **copper intrauterine device (Cu IUD)** is generally contraindicated in women with menorrhagia because it can exacerbate heavy menstrual bleeding. - While an effective contraceptive, it does not offer therapeutic benefits for managing heavy periods. *Hysterectomy* - **Hysterectomy** is a surgical procedure for removing the uterus and is considered a definitive treatment for menorrhagia. - However, it is an **invasive procedure** with irreversible loss of fertility, typically reserved for severe cases where conservative treatments have failed or when other uterine pathology is present.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free